The COX-2 specific inhibitor valdecoxib versus tramadol in acute ankle sprain: A multicenter randomized, controlled trial

American Journal of Sports Medicine

Volumn 34, Issue 6, 2006, Pages 945-955

  Ekman, Evan F ^a   Ruoff, Gary ^b   Kuehl, Kerry ^c   Ralph, Lee ^d   Hormbrey, Philip ^e   Fiechtner, Justus ^f   Berger, Manuela F ^g  

^a Southern Orthopaedic Sports Medicine   (United States)

^b Westside Family Medical Center   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d San Diego Sports Medicine and Family Health Center   (United States)

^e JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^f MICHIGAN STATE UNIVERSITY   (United States)

^g Pfizer Global Pharmaceuticals   (United States)

Author keywords

Cyclooxygenase 2 (COX 2) specific inhibitor; Tramadol; Valdecoxib

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; PLACEBO; TRAMADOL; VALDECOXIB;

ABDOMINAL PAIN; ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANKLE PAIN; ANKLE SPRAIN; ARTICLE; ASTHENIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INJURY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SOMNOLENCE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE; VOMITING; WALKING;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; ANKLE INJURIES; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; HEALTH STATUS; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; SPRAINS AND STRAINS; SULFONAMIDES; TRAMADOL; TREATMENT OUTCOME;

EID: 33646551438     PISSN: 03635465     EISSN: 15523365     Source Type: Journal    
DOI: 10.1177/0363546505283261     Document Type: Article

References (46)

1. American Pain Society Quality of Care Committee. Quality improvement guidelines for the treatment of acute pain and cancer pain. JAMA. 1995;274:1874-1880.
2. Bensen W, Weaver A, Espinoza L, et al. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis: a randomized, controlled comparison with placebo and naproxen. Rheumatology. 2002;41:1008-1016.
3. Bensen WG, Fiechtner JJ, McMillen JI, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. Mayo Clin Proc. 1999;74:1095-1105.
4. Bextra [package insert]. New York, NY: Pfizer Inc; November 2004. Available at: http://www.bextra.com/pdf/bextrapi.pdf. Accessed February 2005.
5. Bouchier-Hayes TA. Naproxen sodium and piroxicam in acute musculo-skeletal disorders. Br J Sports Med. 1984;18:80-83.
6. Camu F, Beecher T, Recker DP, Verburg KM. Valdecoxib, a COX-2-specific inhibitor, is an efficacious, opioid-sparing analgesic in patients undergoing hip arthroplasty. Am J Ther. 2002;9:43-51.
7. Colville MR, Amendola, Butters MA, et al. Clinical Guideline on Ankle Injury. Rosemont, IL: American Academy of Orthopaedic Surgeons; 1999.
8. Committee on Quality Assurance Standards, American Pain Society. American Pain Society quality assurance standards for relief of acute pain and cancer pain. In: Bond M, Charlton J, Woolf C, eds. Proceedings of the VIth World Congress on Pain. New York, NY: Elsevier Science Publishers; 1991:185-189.
9. Conrad KA, Fagan TC, Mackie MJ, Mayshar PV. Effects of ketorolac tromethamine on hemostasis in volunteers. Clin Pharmacol Ther. 1988;43:542-546.
10. Daniels S, Talwalker S, Torri S, Snabes MC, Recker DP, Verburg KM. Valdecoxib, a cyclooxygenase-2-specific inhibitor, is effective and well tolerated in treating primary dysmenorrhea. Obstet Gynecol. 2002;100:350-358.
11. Daniels SE, Desjardins PJ, Talwalker S, Recker DP, Verburg KM. The analgesic efficacy of valdecoxib vs oxycodone/acetaminophen after oral surgery. J Am Dent Assoc. 2002;133:611-621.
12. Desjardins PJ, Shu VS, Recker DP, Verburg KM, Woolf CJ. A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain. Anesthesiology. 2002;97:565-573.
13. Duncan JJ, Farr JE. Comparison of diclofenac sodium and aspirin in the treatment of acute sports injuries. Am J Sports Med. 1988;16:656-659.
14. Ekman EF, Fiechtner JJ, Levy S, Fort JG. Efficacy of celecoxib versus ibuprofen in the treatment of acute pain: a multicenter, double-blind, randomized controlled trial in acute ankle sprain. Am J Orthop. 2002;31:445-451.
15. Fricke J, Varkalis J, Zwillich S, et al. Valdecoxib is more efficacious than rofecoxib in relieving pain associated with oral surgery. Am J Ther. 2002;9:89-97.
16. Garrick JG. Epidemiologic perspective. Clin Sports Med. 1982;1:13-18.
17. Garrick JG. The frequency of injury, mechanism of injury, and epidemiology of ankle sprains. Am J Sports Med. 1977;5:241-242.
18. Gerber JP, Williams GN, Scoville CR, Arciero RA, Taylor DC. Persistent disability associated with ankle sprains: a prospective examination of an athletic population. Foot Ankle Int. 1998;19:653-660.
19. Gierse JK, McDonald JJ, Hauser SD, Rangwala SH, Koboldt CM, Seibert K. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors. J Biol Chem. 1996;271:15810-15814.
20. Goldstein JL, Kivitz AJ, Verburg KM, Recker DP, Palmer RC, Kent JD. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects. Aliment Pharmacol Ther. 2003;18:125-132.
21. Green D, Davies RO, Holmes GI, et al. Effects of diflunisal on platelet function and fecal blood loss. Clin Pharmacol Ther. 1981;30:378-384.
22. Harris SI, Kuss M, Hubbard RC, Goldstein JL. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2- specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther. 2001;23:1422-1428.
23. Heere LP. Piroxicam in acute musculoskeletal disorders and sports injuries. Am J Med. 1988;84:50-55.
24. Jenkins JK, Seligman PJ. Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. Food and Drug Administration Web site. Available at: http://www.fda.gov/cder/drug/ infopage/COX2/NSAIDdecisionMemo.pdf. Accessed January 16, 2006.
25. Jupiter J, Ring D. Approach to minor orthopedic problems of the foot and ankle. In: Goroll AH, Mulley AG Jr, eds. Primary Care Medicine: Office Evaluation and Management of the Adult Patient. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000.
26. Kivitz A, Eisen G, Zhao WW, Bevirt T, Recker DP. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J Fam Pract. 2002;51:530-537.
27. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40:124-132.
28. Leese PT, Talwalker S, Kent JD, Recker DP. Valdecoxib does not impair platelet function. Am J Emerg Med. 2002;20:275-281.
29. Lehmann KA. Tramadol for the management of acute pain. Drugs. 1994;47(suppl 1):19-32.
30. Lewis KS, Han NH. Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm. 1997;54:643-652.
31. Makarowski W, Zhao W, Bevirt T, Recker DP. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip: a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cartilage. 2002;10:290-296.
32. Ogilvie-Harris DJ, Gilbart M. Treatment modalities for soft tissue injuries of the ankle: a critical review. Clin J Sport Med. 1995;5:175-186.
33. Petrella R, Ekman EF, Schuller R, Fort JG. Efficacy of celecoxib, a COX-2-specific inhibitor, and naproxen in the management of acute ankle sprain: results of a double-blind, randomized controlled trial. Clin J Sport Med. 2004;14:225-231.
34. Reig E. Tramadol in musculoskeletal pain - a survey. Clin Rheumatol. 2002;21(suppl 1):S9-S11.
35. Renstrom PA, Konradsen L. Ankle ligament injuries. Br J Sports Med. 1997;31:11-20.
36. Reynolds LW, Hoo RK, Brill RJ, North J, Recker DP, Verburg KM. The COX-2 specific inhibitor, valdecoxib, is an effective, opioid-sparing analgesic in patients undergoing total knee arthroplasty. J Pain Symptom Manage. 2003;25:133-141.
37. Safran MR, Benedetti RS, Bartolozzi AR III, Mandelbaum BR. Lateral ankle sprains: a comprehensive review, part 1: etiology, pathoanatomy, histopathogenesis, and diagnosis. Med Sci Sports Exerc. 1999;31 (suppl 7):S429-S437.
38. Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol. 1995;35:209-219.
39. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-1255.
40. Simon LS, Lanza FL, Lipsky PE, et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis Rheum. 1998;41:1591-1602.
41. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA. 1999;282:1921-1928.
42. Slatyer MA, Hensley MJ, Lopert R. A randomized controlled trial of piroxicam in the management of acute ankle sprain in Australian Regular Army recruits: the Kapooka Ankle Sprain Study. Am J Sports Med. 1997;25:544-553.
43. Weiler JM. Medical modifiers of sports injury: the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in sports soft-tissue injury. Clin Sports Med. 1992;11:625-644.
44. Wolfe MW, Uhl TL, Mattacola CG, McCluskey LC. Management of ankle sprains. Am Fam Physician. 2001;63:93-104.
45. Yepes JP, Ekman E, Levy SD, Fort JG. Efficacy of celecoxib versus diclofenac in the treatment of pain associated with acute ankle sprain: a multicenter, doubleblind, randomized trial [Abstract ABO 507]. Ann Rheum Dis. 2002;61(suppl 1):471-472.
46. Zhang Y, Shaffer A, Portanova J, Seibert K, Isakson PC. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther. 1997;283:1069-1075.